| Name | opigolix |
|---|---|
| Synonyms |
VQ6CK0CITA
(1Z,2R)-N'-({5-[3-(2,5-Difluorophenyl)-2-(1,3-dihydro-2H-benzimidazol-2-ylidene)-3-oxopropanoyl]-2-fluorophenyl}sulfonyl)-2-hydroxypropanimidamide UNII:VQ6CK0CITA Opigolix Propanimidamide, N'-[[5-[3-(2,5-difluorophenyl)-2-(1,3-dihydro-2H-benzimidazol-2-ylidene)-1,3-dioxopropyl]-2-fluorophenyl]sulfonyl]-2-hydroxy-, (1Z,2R)- UNII-VQ6CK0CITA |
| Description | Opigolix is a Gonadotropin-releasing hormone (GnRH) receptor antagonist, used for the research of endometriosis and rheumatoid arthritis. |
|---|---|
| Related Catalog | |
| Target |
GnRH receptor[1] |
| In Vitro | Opigolix (Compound 726) is a GnRH receptor antagonist, used for the research of sex hormone-dependent diseases, particularly GnRH-related diseases[1]. |
| References |
[1]. Hirano, Masaaki, et al. PROPANE-1,3-DION DERIVATIVE OR SALT THEREOF. WO 2006106812 A1. |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Boiling Point | 706.9±70.0 °C at 760 mmHg |
| Molecular Formula | C25H19F3N4O5S |
| Molecular Weight | 544.502 |
| Flash Point | 381.3±35.7 °C |
| Exact Mass | 544.102844 |
| LogP | 0.45 |
| Vapour Pressure | 0.0±2.4 mmHg at 25°C |
| Index of Refraction | 1.665 |